Literature DB >> 32653872

FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference.

Marie-Liesse Piketty1, Severine Brabant1, Jean-Claude Souberbielle1, Gérard Maruani1, Christelle Audrain2, Anya Rothenbuhler2, Dominique Prié1, Agnès Linglart2.   

Abstract

Entities:  

Keywords:  FGF23; X-linked hypophosphataemia (XLH); burosumab; immunoassay; interference

Year:  2020        PMID： 32653872     DOI： 10.1515/cclm-2020-0460

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN： 1434-6621            Impact factor:   3.694


× No keyword cloud information.
  9 in total

Review 1.  The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations.

Authors:  Annemieke C Heijboer; Etienne Cavalier
Journal:  Calcif Tissue Int       Date:  2022-06-04       Impact factor: 4.333

Review 2.  Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.

Authors:  Andrea Trombetti; Nasser Al-Daghri; Maria Luisa Brandi; Jorge B Cannata-Andía; Etienne Cavalier; Manju Chandran; Catherine Chaussain; Lucia Cipullo; Cyrus Cooper; Dieter Haffner; Pol Harvengt; Nicholas C Harvey; Muhammad Kassim Javaid; Famida Jiwa; John A Kanis; Andrea Laslop; Michaël R Laurent; Agnès Linglart; Andréa Marques; Gabriel T Mindler; Salvatore Minisola; María Concepción Prieto Yerro; Mario Miguel Rosa; Lothar Seefried; Mila Vlaskovska; María Belén Zanchetta; René Rizzoli
Journal:  Nat Rev Endocrinol       Date:  2022-04-28       Impact factor: 43.330

3.  X-linked hypophosphatemia, obesity and arterial hypertension: data from the XLH21 study.

Authors:  Louisa Bloudeau; Agnès Linglart; Sacha Flammier; Aurélie Portefaix; Aurélia Bertholet-Thomas; Sanaa Eddiry; Anna Barosi; Jean-Pierre Salles; Valérie Porquet-Bordes; Anya Rothenbuhler; Christelle Roger; Justine Bacchetta
Journal:  Pediatr Nephrol       Date:  2022-06-27       Impact factor: 3.714

Review 4.  Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.

Authors:  Michaël R Laurent; Jean De Schepper; Dominique Trouet; Nathalie Godefroid; Emese Boros; Claudine Heinrichs; Bert Bravenboer; Brigitte Velkeniers; Johan Lammens; Pol Harvengt; Etienne Cavalier; Jean-François Kaux; Jacques Lombet; Kathleen De Waele; Charlotte Verroken; Koenraad van Hoeck; Geert R Mortier; Elena Levtchenko; Johan Vande Walle
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-19       Impact factor: 5.555

5.  Long-term use of burosumab for the treatment of tumor-induced osteomalacia.

Authors:  C Crotti; F Zucchi; C Alfieri; R Caporali; M Varenna
Journal:  Osteoporos Int       Date:  2022-08-04       Impact factor: 5.071

Review 6.  Rickets guidance: part I-diagnostic workup.

Authors:  Dieter Haffner; Maren Leifheit-Nestler; Andrea Grund; Dirk Schnabel
Journal:  Pediatr Nephrol       Date:  2021-12-15       Impact factor: 3.651

7.  Clinical and genetic characteristics of 29 Chinese patients with X-linked hypophosphatemia.

Authors:  Tian Xu; Xiaohui Tao; Zhenlin Zhang; Hua Yue
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

8.  Rickets guidance: part II-management.

Authors:  Dieter Haffner; Maren Leifheit-Nestler; Andrea Grund; Dirk Schnabel
Journal:  Pediatr Nephrol       Date:  2022-03-29       Impact factor: 3.651

Review 9.  Hormone Immunoassay Interference: A 2021 Update.

Authors:  Khaldoun Ghazal; Severine Brabant; Dominique Prie; Marie-Liesse Piketty
Journal:  Ann Lab Med       Date:  2022-01-01       Impact factor: 3.464
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.